Actemra

DRUG4 trials

Sponsors

F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG, University of Zurich, Biogen

Conditions

Healthy VolunteerMetastatic breast cancerMultiple myeloma (MM)Pyrexiaand HER2 positive and HER2 low breast cancer (HER2+/HER2-low BC)hormone receptor positive breast cancer (HR+ BC)including triple negative breast cancer (TNBC)

Phase 1

An Open-label, Randomized Phase Ib/II Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants with Relapsed or Refractory Multiple Myeloma

CompletedCTIS2023-503689-21-00

F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AGMultiple myeloma (MM)

Start: 2023-12-05End: 2025-04-14Target: 73Updated: 2024-10-10

A Study to Evaluate the Pharmacokinetics, Safety and Immunogenicity of BIIB800 Subcutaneously (SC) Compared to Actemra® in Healthy Male Participants

CompletedNCT06262477

BiogenHealthy Volunteer

Start: 2024-01-02End: 2024-10-04Updated: 2025-10-06

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients with Metastatic Breast Cancer (MORPHEUS-panBC)

RecruitingCTIS2023-503629-20-00

F. Hoffmann-La Roche AGand HER2 positive and HER2 low breast cancer (HER2+/HER2-low BC), hormone receptor positive breast cancer (HR+ BC), including triple negative breast cancer (TNBC) +1

Start: 2018-06-27Target: 50Updated: 2025-08-14

Phase 2

Pyrexia Management Using an IL-6 Antibody in BRAF+ Melanoma Patients Treated with Dabrafenib/ Trametinib +/- Immunotherapy

TerminatedNCT04652258

University of ZurichPyrexia

Start: 2021-02-01End: 2021-10-31Updated: 2024-11-01